Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1651-1664

  Sia, Kian Chuan ^a   Huynh, Hung ^a   Chung, Alexander Yaw Fui ^b   Ooi, London Lucien Peng Jin ^b   Lim, Kiat Hon ^c   Hui, Kam Man ^a,d,f,g   Lam, Paula Yeng Po ^a,e,f,g  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Departments of General Surgery   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d Departments of Biochemistry   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CYTOSINE DEAMINASE; FLUOROURACIL; LUCIFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENE VECTOR; HUMAN; HUMAN CELL; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER GRAFT; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE HOMOLOGY; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR CELL; XENOGRAFT;

ADENOSINE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882255368     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0056     Document Type: Article

References (53)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132: 2557-76.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-2.
3. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: The first wave of translational clinical trials. Transl Res 2013;161:355-64.
6. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13: 1929-39.
7. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
8. Muller GA, Engeland K. The central role of CDE/CHR promoter elements in the regulation of cell cycle-dependent gene transcription. FEBS J 2010;277:877-93.
9. Liu N, Lucibello FC, Korner K, WolfraimLA, Zwicker J, Muller R CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Nucleic Acids Res 1997;25: 4915-20.
10. Philips A, Chambeyron S, Lamb N, Vie A, Blanchard JM. CHF: A novel factor binding to cyclin A CHR corepressor element. Oncogene 1999;18:6222-32.
11. Muller GA, Quaas M, Schumann M, Krause E, Padi M, Fischer M, et al. The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res 2012;40:1561-78.
12. Quaas M, Muller GA, Engeland K. p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle 2012;11:4661-72.
13. Wang GY, Ho IA, Sia KC, Miao L, Hui KM, Lam PY. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther 2007;18: 222-31.
14. Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA, et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther 2007;15:1129-36.
15. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59:1417-21.
16. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009;14:4517-45.
17. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012;130:2557-67.
18. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009;8:1579-88.
19. Aoki R, Chiba T, Miyagi S, Negishi M, Konuma T, Taniguchi H, et al. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatol 2010;52: 854-63.
20. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011;19: 86-100.
21. Sia KC, Huynh H, Chinnasamy N, Hui KM, Lam PY. Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging. Gene Ther 2012;19: 532-42.
22. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: A useful model for testing drugs. Clin Cancer Res 2006;12:4306-14.
23. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 2008;17:411-7.
24. Foka P, Pourchet A, Hernandez-Alcoceba R, Doumba PP, Pissas G, Kouvatsis V, et al. Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J Gene Med 2010;12:956-67.
25. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 1998;58: 985-90.
26. Zhou Q, He Q, Liang LJ. Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2003;9:2450-4.
27. Wang X, Meng X, Sun X, Liu M, Gao S, Zhao J, et al. Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle 2009;8:1567-70.
28. Wang LH, Huang W, Lai MD, Su IJ. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis 2012;33:466-72.
29. Kim DH, Park SE, Kim M, Ji YI, Kang MY, Jung EH, et al. A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver, and lung cancers. Cancer 2011;117:4080-91.
30. Chen XL, Zhou L, Yang J, Shen FK, Zhao SP, Wang YL. Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS. Mol Med Rep 2010;3:589-96.
31. Topic A, Ljujic M, Radojkovic D. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon 2012;12:e7042.
32. Qin X, Chen Q, Sun C, Wang C, Peng Q, Xie L, et al. High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques. Med Oncol 2013;30:420.
33. Fu X, Rivera A, Tao L, De Geest B, Zhang X. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol Ther 2012;20:339-46.
34. Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, et al. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: Relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther 2012;19:160-70.
35. Lu YC, Chen YJ, Yu YR, Lai YH, Cheng JC, Li YF, et al. Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma. Oncol Rep 2012;28:21-6.
36. Warmann SW, Armeanu S, Heigoldt H, Ruck P, Vonthein R, Heitmann H, et al. Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer 2009;53:145-51.
37. Altanerova V, Cihova M, Babic M, Rychly B, Ondicova K, Mravec B, et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase:uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 2012;130:2455-63.
38. Yi BR, Kim SU, KimYB, Lee HJ, Cho MH, Choi KC. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. Oncol Rep 2012;27:1823-8.
39. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44:240-51.
40. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracilmediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994;29:519-23.
41. Kievit E, Nyati MK, Ng E, Stegman LD, Parsels J, Ross BD, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000;60:6649-55.
42. Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, et al. Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012;20:1689-98.
43. Spear PG. Herpes simplex virus: Receptors and ligands for cell entry. Cell Microbiol 2004;6:401-10.
44. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000;60:2790-5.
45. Song TJ, Eisenberg DP, Adusumilli PS, Hezel M, Fong Y. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. J Gastrointest Surg 2006;10:532-42.
46. Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010;21:1119-28.
47. Lu B, Gupta S, Federoff H. Ex vivo hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector. Hepatology 1995;21:752-9.
48. Muller L, Saydam O, Saeki Y, Heid I, Fraefel C. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol Methods 2005;123:65-72.
49. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133? HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-58.
50. Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao W, et al. CD133(?) EpCAM(?) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci 2012;8:992-1004.
51. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050-63.
52. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 2011; 118:2830-9.
53. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012;11:1735-46.